Drug Trial Radar · NCT07321912
Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma
Last checked: Nov 20, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
406
Planned (sponsor's estimate)
Start
Jun 5, 2026
Primary completion
Jun 1, 2031
Study completion Jun 1, 2036
Sponsor
- Lead sponsor
- Milton S. Hershey Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- USWM, LLC (dba US WorldMeds)
- First posted
- Jan 7, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 0 years, up to 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Ewing sarcoma (EWS) and osteosarcoma primarily affect adolescents and young adults. Common treatments include chemotherapy, surgery and radiation, however, there have been few recent advancements in the standard of care. By incorporating eflornithine (DFMO) as an additional therapy and/or maintenance therapy we hope to safely observe improved event-free survival and overall survival. There are 5 cohorts covered under this master protocol.
Conditions
- Osteosarcoma
- Ewing Sarcoma
Interventions
EflornithineDrug
Oral twice daily
TopotecanDrug
IV
CyclophosphamideDrug
IV
VincristineDrug
IV
DoxorubicinDrug
IV
IfosfamideDrug
IV
EtoposideDrug
IV
CisplatinDrug
IV
MethotrexateDrug
IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Cohort 1 participants with relapse free survival (RFS) during studyTime frame: 2 years plus 5 years follow up
- Number of Cohort 2 participants with event-free survival (EFS) during studyTime frame: 2 years plus 5 years follow up
- Cohort 3: Number of Cohort 3 participants at 12 months with disease controlTime frame: 1 year plus 5 years follow up
- Cohort 4A: Number of Cohort 4A participants with event-free survival (EFS) during studyTime frame: 2 years plus 5 years follow up
- Cohort 4B: Number of Cohort 4B participants with event-free survival (EFS) during studyTime frame: 2 years plus 5 years follow up
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
St. Joseph's Children's Hospital
Tampa, Florida · Recruiting
Randall Children's Hospital
Portland, Oregon · Recruiting
Penn State Milton S. Hershey Medical Center and Children's Hospital
Hershey, Pennsylvania · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.